Compare Chubb Ltd (CB) vs Summit Therapeutics Inc (SMMT) Price & Performance

Chubb Limited (CB) trades at $343.12, down 1.49% on the day, with a neutral technical signal. The stock shows strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $7.26 versus $6.77 expected, and a net income margin of 17.96% for 2025. Revenue has grown from $43.1B in 2022 to $59.8B in 2025, with further growth projected. A recent dividend of $1.02 was declared for H1-26, payable July 2, 2026.

The outlook remains positive given analyst consensus favoring Buy ratings (52.38%) and a price target of $366.83, implying ~7% upside. Risks include potential volatility from macroeconomic factors and competitive pressures in the insurance sector. The company’s disciplined underwriting and investment income growth support long-term value, but investors should weigh valuation multiples against sector peers.

Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.

The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.